Borate Compound Synthesis via Esterifying Agent Selection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current borate compounds used as proteasome inhibitors face challenges in refinement, purification, and production costs due to the complexity of their structural components, such as citric acid, which complicates their synthesis and increases costs.
Innovation Solution
A new borate compound with a specific structural formula derived from boric acid esterifying agents like salicylic acid, mandelic acid, or lactic acid, forming a 5 to 12-membered ring, which is easier to synthesize and purify, and has enhanced biological activity and safety.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If citric acid is used as the boric acid esterifying agent to form MLN9708, then the compound can be synthesized in one step, but the compound becomes difficult to refine and purify due to multiple reaction sites forming both five-membered and six-membered cyclic structures
Solution Approach 1:
The patent extracts the problematic multifunctional citric acid moiety and replaces it with simpler, single-site esterifying agents (salicylic acid, mandelic acid, lactic acid, or amino acids). This removal of the complex multi-reactive center eliminates the formation of multiple cyclic structures, thereby simplifying purification while maintaining the core borate compound functionality and proteasome inhibition activity.
2Power
If citric acid with multiple reaction sites is used, then the synthesis reaction is highly active, but the production cost increases due to the complexity of refinement and purification processes
Solution Approach 1:
The patent employs simple, readily available, and inexpensive esterifying agents (salicylic acid, mandelic acid, lactic acid, or amino acids) that can be easily purified through standard methods. These simpler compounds replace the expensive and difficult-to-purify citric acid derivative, reducing production costs while maintaining sufficient reaction activity to form the desired borate compound.
3Reliability
If complex structures like MLN9708 are used, then the compound shows good proteasome inhibition activity, but the stability under high-temperature and high-humidity conditions is reduced
Solution Approach 1:
The patent changes the chemical parameters of the esterifying agent from the complex citric acid structure to simpler aromatic or aliphatic structures (salicylic acid, mandelic acid, lactic acid). This structural parameter change enhances the compound's stability under high-temperature and high-humidity conditions while preserving the essential borate-glycolic acid motif required for proteasome inhibition activity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The new borate compound demonstrates strong activity and high safety, with improved stability and reduced production costs, outperforming existing compounds like MLN9708 and MLN2238 in high-temperature and high-humidity conditions.
Implementation Method 1
a boric acid esterifying agent is selected from the group consisting of α-hydroxy acid, β-hydroxy acid, amino acid and R3—NH—R4
Implementation Method 2
the circular portion is an optionally substituted ring in which a boron atom is directly linked to two oxygen atoms and formed jointly with other fragments
Data Source
AI summary
A borate compound serving as a proteasome inhibitor, a preparation method for the borate compound and uses thereof.